Review of utility values for economic modeling in type 2 diabetes

Value in Health

Volumn 17, Issue 4, 2014, Pages 462-470

  Beaudet, Amélie ^a   Clegg, John ^a   Thuresson, Per Olof ^a   Lloyd, Adam ^a   McEwan, Phil ^b  

^a IQVIA   (United States)

^b SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

diabetes; EQ 5D; quality of life; systematic review; utility

Indexed keywords

AMPUTATION; CATARACT; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; DIABETIC RETINOPATHY; ECONOMIC EVALUATION; HEART FAILURE; HEART INFARCTION; HEMODIALYSIS; HUMAN; HYPOGLYCEMIA; ISCHEMIC HEART DISEASE; KIDNEY GRAFT; NETHERLANDS; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL DISTRIBUTION; OUTCOMES RESEARCH; PERIPHERAL VASCULAR DISEASE; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROTEINURIA; PUBLICATION; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; SYSTEMATIC REVIEW; VISUAL IMPAIRMENT;

DIABETES; EQ-5D; QUALITY OF LIFE; SYSTEMATIC REVIEW; UTILITY;

COST-BENEFIT ANALYSIS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; HEALTH STATUS; HUMANS; MODELS, ECONOMIC; QUALITY OF LIFE;

EID: 84903268047     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2014.03.003     Document Type: Article

References (43)

1. N. Hex, C. Bartlett, and D. Wright et al. Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs Diabet Med 29 2012 855 862
2. N. Holman, N.G. Forouhi, E. Goyder, and S.H. Wild The Association of Public Health Observatories (APHO) Diabetes Prevalence Model: estimates of total diabetes prevalence for England, 2010-2030 Diabet Med 28 5 2011 575 582
3. IMS Knowledge Link version 5. Drugs used in diabetes currently in phase III or in pre-registration. IMS Health, Lifecycle R&D Focus Source. Available from: http://knowledgelink.imshealth.com/. [Accessed March 13, 2013].
4. National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. 2008. Available from: http://www.nice.org.uk/media/B52/ A7/TAMethodsGuideUpdatedJune2008.pdf. [Accessed March 13, 2013].
5. D. Papaioannou, J. Brazier, and S. Paisley TSD 9 The Identification, Review and Synthesis of Health State Utility Values from the Literature Decision Support Unit, School of Health and Related Research 2010 University of Sheffield Sheffield, UK
6. J. Brazier, and L. Longworth TSD 8 An Introduction to the Measurement and Valuation of Health for NICE Submissions 2011 Decision Support Unit, ScHARR, University of Sheffield Sheffield, UK
7. National Institute for Health and Care Excellence. Single technology appraisal (STA), Specification for manufacturer/sponsor submission of evidence. Rotterdam, The Netherlands: NICE, 2012.
8. R. Rabin, M. Oemar, and M. Oppe EQ-5D-3L User Guide (Version 4.0) Rotterdam, The Netherlands: EuroQol Group 2011
9. J. Holmes, S. McGill, and P. Kind et al. Health-related quality of life in type 2 diabetes (TARDIS-2) Value Health 3 Suppl. 1 2000 47 51
10. D.J. Wexler, R.W. Grant, and E. Wittenberg et al. Correlates of health-related quality of life in type 2 diabetes Diabetologia 49 2006 1489 1497
11. B. Conner-Spady, and M.E. Suarez-Almazor Variation in the estimation of quality-adjusted life-years by different preference-based instruments Med Care 41 2003 791 801
12. J.A. Kopec, and K.D. Willison A comparative review of four preference-weighted measures of health-related quality of life J Clin Epidemiol 56 2003 317 325
13. A.J. Palmer, S. Roze, and W.J. Valentine et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making Curr Med Res Opin 20 Suppl. 1 2004 S5 26
14. P.M. Clarke, A.M. Gray, and A. Briggs et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68) Diabetologia 47 2004 1747 1759
15. P. McEwan, J.R. Peters, K. Bergenheim, and C.J. Currie Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster) Curr Med Res Opin 22 2006 121 129
16. Mount Hood 4 Modeling Group Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting Diabetes Care 30 2007 1638 1646
17. T.W. Lung, A.J. Hayes, and A. Hayen et al. A meta-analysis of health state valuations for people with diabetes: explaining the variation across methods and implications for economic evaluation Qual Life Res 20 2011 1669 1678
18. C.J. Currie, C.L. Morgan, and C.D. Poole et al. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes Curr Med Res Opin 22 2006 1523 1534
19. D.H. Smith, E.S. Johnson, and A. Russell et al. Lower visual acuity predicts worse utility values among patients with type 2 diabetes Qual Life Res 17 2008 1277 1284
20. P. Dolan Modeling valuations for EuroQol health states Med Care 35 1997 1095 1108
21. P. Clarke, A. Gray, and R. Holman Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62) Med Decis Making 22 2002 340 349
22. A. Bagust, and S. Beale Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data Health Econ 14 2005 217 230
23. J.B. Wasserfallen, G. Halabi, and P. Saudan et al. Quality of life on chronic dialysis: comparison between haemodialysis and peritoneal dialysis Nephrol Dial Transplant 19 2004 1594 1599
24. E.K. Fenwick, J. Xie, and J. Ratcliffe et al. The impact of diabetic retinopathy and diabetic macular edema on health-related quality of life in type 1 and type 2 diabetes Invest Ophthalmol Vis Sci 53 2012 677 684
25. A. Laupacis, P. Keown, and N. Pus et al. A study of the quality of life and cost-utility of renal transplantation Kidney Int 50 1996 235 242
26. B.A. Kiberd, and K.K. Jindal Screening to prevent renal failure in insulin dependent diabetic patients: an economic evaluation BMJ 311 1995 1595 1599
27. P. Sakthong, R. Charoenvisuthiwongs, and R. Shabunthom A comparison of EQ-5D index scores using the UK, US, and Japan preference weights in a Thai sample with type 2 diabetes Health Qual Life Outcomes 6 2008 1
28. P. Glasziou, J. Alexander, E. Beller, and P. Clarke Which health-related quality of life score? A comparison of alternative utility measures in patients with type 2 diabetes in the ADVANCE trial Health Qual Life Outcomes 5 2007 21
29. N. Kontodimopoulos, E. Pappa, and Z. Chadjiapostolou et al. Comparing the sensitivity of EQ-5D, SF-6D and 15D utilities to the specific effect of diabetic complications Eu J Health Econ 13 2012 111 120
30. M. Langelaan, M.R. de Boer, and R.M. van Nispen et al. Impact of visual impairment on quality of life: a comparison with quality of life in the general population and with other chronic conditions Ophthalmic Epidemiol 14 3 2007 119 126
31. L.M. Lamers, P.F. Stalmeier, and J. McDonnell et al. Measuring the quality of life in economic evaluations: the Dutch EQ-5D tariff [in Dutch] Ned Tijdschr Geneeskd 149 28 2005 1574 1578
32. W.J. Lee, K.H. Song, and J.H. Noh et al. Health-related quality of life using the EuroQol 5D questionnaire in Korean patients with type 2 diabetes J Korean Med Sci 27 2012 255 260
33. M.W. Jo, S.C. Yun, and S.I. Lee Estimating quality weights for EQ-5D health states with the time trade-off method in South Korea Value Health 11 2008 1186 1189
34. A. Lloyd, B. Nafees, and S. Gavriel et al. Health utility values associated with diabetic retinopathy Diabet Med 25 2008 618 624
35. E. Marrett, T. Stargardt, P. Mavros, and C.M. Alexander Patient-reported outcomes in a survey of patients treated with oral antihyperglycaemic medications: associations with hypoglycaemia and weight gain Diabetes Obes Metab 11 12 2009 1138 1144
36. J.W. Shaw, J.A. Johnson, and S.J. Coons US valuation of the EQ-5D health states: development and testing of the D1 valuation model Med Care 43 2005 203 220
37. L.S. Matza, N. Yurgin, and K.S. Boye et al. Obese versus non-obese patients with type 2 diabetes: patient-reported outcomes and utility of weight change Curr Med Res Opin 23 2007 2051 2062
38. D.J. O'Reilly, F. Xie, and E. Pullenayegum et al. Estimation of the impact of diabetes-related complications on health utilities for patients with type 2 diabetes in Ontario, Canada Qual Life Res 20 2011 939 943
39. J.H.M. Quah, N. Luo, and W.Y. Ng et al. Health-related quality of life is associated with diabetic complications, but not with short-term diabetic control in primary care Ann Acad Med Singapore 40 6 2011 276 286
40. W.K. Redekop, M.A. Koopmanschap, and R.P. Stolk et al. Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes Diabates Care 25 2002 458 463
41. O. Solli, K. Stavern, and I.S. Kristiansen Health-related quality of life in diabetes: the associations of complications with EQ-5D scores Health Qual Life Outcomes 8 2010 18
42. P.W. Sullivan, V.H. Ghushchyan, and R. Ben-Joseph The impact of obesity on diabetes, hyperlipidemia and hypertension in the United States Qual Life Res 17 2008 1063 1071
43. P. Vexiau, P. Mavros, and G. Krishnarajah et al. Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France Diabetes Obes Metab 10 Suppl. 1 2008 16 24